The DOI matches its Crossref record; 405 of the 406 references it cites were found in a registry or an index.
Reduced Vancomycin Susceptibility in Staphylococcus aureus , Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications
Open accessAbstract
SUMMARY: The emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past decade has provided a challenge to diagnostic microbiologists to detect these strains, clinicians treating patients with infections due to these strains, and researchers attempting to understand the resistance mechanisms. Recent data show that these strains have been detected globally and in many cases are associated with glycopeptide treatment failure; however, more rigorous clinical studies are required to clearly define the contribution of hVISA to glycopeptide treatment outcomes. It is now becoming clear that sequential point mutations in key global regulatory genes contribute to the hVISA and VISA phenotypes, which are associated predominately with cell wall thickening and restricted vancomycin access to its site of activity in the division septum; however, the phenotypic features of these strains can vary because the mutations leading to resistance can vary. Interestingly, changes in the staphylococcal surface and expression of agr are likely to impact host-pathogen interactions in hVISA and VISA infections. Given the subtleties of vancomycin susceptibility testing against S. aureus , it is imperative that diagnostic laboratories use well-standardized methods and have a framework for detecting reduced vancomycin susceptibility in S. aureus .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Due to the difficulties on detecting these strains, vancomycin failures have been increasingly reported in deep-seated infections.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“Indeed, S. aureus within the range of susceptibility, with vancomycin MICs > 1 and ≤ 2 μg/ml have been more frequently associated with the hVISA phenotype.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“These global homeostatic changes appear to lead to a reduced autolytic activity with thickened cell wall and an increase amount of free D-Ala-D-Ala dipeptides with less peptidoglycan cross-linking (101, 104).”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“Phenotypically, hVISA/VISA strains exhibit distinct metabolic characteristics that may include i) increase in fructose utilization, ii) increased fatty acid metabolism, iii) impaired acetate metabolism and tricarboxylic acid cycle, iv) decrease in glutamate availability, and iv) increase expression of cell wall synthesis genes.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“As the “resistant” subpopulation is difficult to identify, detection of hVISA becomes very challenging and some S. aureus strains reported as “susceptible” to vancomycin by standard susceptibility testing may still exhibit this phenotype (101).”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“In addition, VISA strains bind vancomycin more avidly than their non –VISA counterparts, however, diffusion of the antibiotic molecule into the inner part of the cell wall appears to be impaired.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“Finally, a striking feature of many hVISA/VISA strains is the ability to revert from one phenotype to another (or even to a fully vancomycin susceptible phenotype) in the absence of vancomycin exposure.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,018
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
Lew, D. P., & Waldvogel, F. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16727-5 · Cited by 1,988
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Vandenesch, F., Naimi, T. S., Enright, M. C., Lina, G., Nimmo, G. R., Heffernan, H., Liassine, N., Bes, M., Greenland, T., Reverdy, M. E., et al. (2003) · Emerging infectious diseases · doi:10.3201/eid0908.030089 · Cited by 1,718
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
The Changing Epidemiology of Staphylococcus aureus ?
Chambers, H. F. “. (2001) · Emerging infectious diseases · doi:10.3201/eid0702.010204 · Cited by 1,419
Plasmid-Mediated Resistance to Vancomycin and Teicoplanin in Enterococcus Faecium
Leclercq, R., Derlot, E., Duval, J., & Courvalin, P. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807213190307 · Cited by 1,411
Diekema, D. J., Pfaller, M. A., Schmitz, F., Smayevsky, J., Bell, J. M., Jones, R. N., Beach, M. L., & SENTRY Participants Group (2001) · Clinical Infectious Diseases · doi:10.1086/320184 · Cited by 1,363
Research works printed but not linked: 1
- Ferraz, V., A. G. Duse, M. Kassel, A. D. Black, T. Ito, and K. Hiramatsu. 2000. Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S. Afr. Med. J.90:1113.
Cited by
Sorted by citations
Items 401–500 of 962
Li, L., Yeaman, M. R., Bayer, A. S., & Xiong, Y. Q. (2019) · Antibiotics · doi:10.3390/antibiotics8020071 · Cited by 21
Increased Release Time of Antibiotics from Bone Allografts through a Novel Biodegradable Coating
Hornyák, I., Madácsi, E., Kalugyer, P., Vácz, G., Horvathy, D. B., Szendrői, M., Han, W., & Lacza, Z. (2014) · BioMed Research International · doi:10.1155/2014/459867 · Cited by 21
Chen, C., Huang, Y., & Shie, S. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01414 · Cited by 22
Population diversity jeopardizes the efficacy of antibiotic cyclingPreprint
Jiao, Y. J., Baym, M., Veres, A., & Kishony, R. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/082107 · Cited by 22
Lin, G., Pankuch, G. A., Appelbaum, P. C., & Kosowska-Shick, K. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02932-14 · Cited by 20
Analysis of proteins and chiral drugs based on vancomycin covalent capillary electrophoretic coating
Xing, J., Wang, F., Cong, H., Wang, S., Shen, Y., & Yu, B. (2020) · The Analyst · doi:10.1039/d0an02018d · Cited by 20
Douglas, E. J. A., Marshall, B., Alghamadi, A., Joseph, E. A., Duggan, S., Vittorio, S., Luca, L. D., Serpi, M., & Laabei, M. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00250 · Cited by 20
Hemmati, J., Chegini, Z., & Arabestani, M. R. (2023) · Journal of Nanomaterials · doi:10.1155/2023/5298565 · Cited by 20
Hattangady, D. S., Singh, A. K., Muthaiyan, A., Jayaswal, R. K., Gustafson, J. E., ULANOV, A. V., Zhong, L., Wilkinson, B. J., & Pfeltz, R. F. (2015) · Antibiotics · doi:10.3390/antibiotics4010076 · Cited by 20
Murray, B. E., Arias, C. A., & Nannini, E. C. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00030-8 · Cited by 21
Paudel, A., Hamamoto, H., Panthee, S., Kaneko, K., Matsunaga, S., Kanai, M., Suzuki, Y., & Sekimizu, K. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00712 · Cited by 20
Kim, M. K., Lee, T., Jung, M., Park, K., & Chong, Y. (2018) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00380 · Cited by 20
Kateete, D. P., Asiimwe, B., Mayanja, R., Najjuka, C. F., & Rutebemberwa, E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229026 · Cited by 20
Friberg, C., Haaber, J., Vestergaard, M. R., Fait, A., Perrot, V., Levin, B. R., & Ingmer, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-69962-4 · Cited by 20
Park, K., Lee, Y., Hong, H., Kim, T., Park, H. J., Park, S.-Y., Moon, S. M., Chong, Y. P., Kim, S., Lee, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046389 · Cited by 20
Datta, S., Pal, N. K., & Nandy, A. K. (2011) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/s1995-7645(11)60218-6 · Cited by 20
Okado, J. B., Avaca-Crusca, J. S., Oliveira, A. L., Dabul, A. N. G., & Camargo, I. L. B. D. C. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.05.001 · Cited by 20
Resistance to Glycopeptide Antibiotics
Lebreton, F., & Cattoir, V. (2019) · Wiley eBooks · doi:10.1002/9781119593522.ch3 · Cited by 22
Taj, Z., & Chattopadhyay, I. (2024) · Springer eBooks · doi:10.1007/978-981-99-8799-3_8 · Cited by 19
Staphylococcus aureus response and adaptation to vancomycin
Fait, A., Silva, S. F., Abrahamsson, J. Å. H., & Ingmer, H. (2024) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2024.04.006 · Cited by 19
Current Trends of Emergence and Spread of Vancomycin-Resistant Enterococci
Werner, G. (2012) · InTech eBooks · doi:10.5772/29791 · Cited by 19
Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?
López-Cortés, L. E., Velasco, C., Retamar, P., del Toro, M. D., Gálvez-Acebal, J., de Cueto, M., Garcı́a, I., Caballero, F. J., Pascual, Á., & Rodríguez‐Baño, J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv133 · Cited by 19
Surface immobilization of active vancomycin on calcium aluminum oxide
Palchesko, R. N., McGowan, K. A., & Gawalt, E. S. (2010) · Materials Science and Engineering C · doi:10.1016/j.msec.2010.12.003 · Cited by 19
Alexander, E. L., Gardete, S., Bar, H., Wells, M. T., Tomasz, A., & Rhee, K. Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097137 · Cited by 19
Ionescu, R., Mediavilla, J. R., Chen, L., Grigorescu, D. O., Idomir, M. E., Kreiswirth, B. N., & Roberts, R. B. (2010) · Microbial Drug Resistance · doi:10.1089/mdr.2010.0059 · Cited by 19
High-Level Vancomycin-Resistant Staphylococcus aureus (VRSA) in Iran: A Systematic Review
Askari, E., Zarifian, A., Pourmand, M. R., & Naderinasab, M. (2013) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 19
Giulieri, S. G., Holmes, N. E., Stinear, T. P., & Howden, B. P. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1233815 · Cited by 17
Self-citationSingh, N. B., Yim, J., Jahanbakhsh, S., Sakoulas, G., & Rybak, M. J. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.03.020 · Cited by 19
Ferraz, M. C., Mano, R. A., Hartwig, D., Maia, D. S. V., Silva, W., Savegnago, L., Lenardao, E. J., & Jacob, R. G. (2017) · Medicines · doi:10.3390/medicines4020039 · Cited by 19
Kondo, S., Phokhaphan, P., Tongsima, S., Ngamphiw, C., Phornsiricharoenphant, W., Ruangchai, W., Disratthakit, A., Tingpej, P., Mahasirimongkol, S., Lulitanond, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05898-1 · Cited by 19
Palavecino, E. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9849-4_1 · Cited by 20
High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis
Meng, L., Fang, Y., Chen, Y., Zhu, H., & Long, R. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000182 · Cited by 20
Silveira, A. C. O., da Cunha, G. R., Caierão, J., de Córdova, C. M. M., & d’Azevedo, P. A. (2015) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2015.04.009 · Cited by 19
Gao, C., Dai, Y., Chang, W., Fang, C., Wang, Z., & Ma, X. (2019) · Microbes and Infection · doi:10.1016/j.micinf.2019.04.003 · Cited by 19
Article Commentary: The Continued Challenge of Staphylococcus aureus in the Surgical Patient
Fry, D. E. (2013) · The American Surgeon · doi:10.1177/000313481307900102 · Cited by 32
Vancomycin-Resistant Staphylococcus aureus Isolates from HIV Positive Patients in Imo State, Nigeria
Emeka-Nwabunnia, I. (2015) · Science Journal of Public Health · doi:10.11648/j.sjph.s.2015030501.11 · Cited by 18
Local antibiotic therapy in infection of arteficial joints
Азатович, К. Т., Akhtyamov, I. F., Гильмутдинов, И. Ш., Биктемировна, Г. Э., Константинович, Е. И., Алиев, Э. И., & Исмаилов, Х. Г. (2014) · Kazan medical journal · doi:10.17816/kmj1526 · Cited by 18
Ju, M., Huang, Y., Xu, X., Qian, Y., Bi, Y., Liu, S., Dong, S., Yuan, J., & Lin, D. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-932 · Cited by 18
Zarkan, A., Macklyne, H.-R., Chirgadze, D. Y., Bond, A. D., Hesketh, A. R., & Hong, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-04868-2 · Cited by 18
Vidor, C. J., Bulach, D., Awad, M. M., & Lyras, D. (2019) · BMC Microbiology · doi:10.1186/s12866-019-1427-5 · Cited by 19
Entenza, J. M., Veloso, T. R., Vouillamoz, J., Giddey, M., Majcherczyk, P. A., & Moreillon, P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00402-11 · Cited by 18
The msaABCR Operon Regulates Resistance in Vancomycin-Intermediate Staphylococcus aureus Strains
Samanta, D., & Elasri, M. O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03280-14 · Cited by 18
da Cunha, I. V., Oliveira, D. D. D. S., Calefi, G. G., Silva, N. B. S., Martins, C. H. G., Júnior, C. D. O. R., & Tsubone, T. M. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117197 · Cited by 17
Periferakis, A., Periferakis, A.-T., Troumpata, L., Periferakis, K., Georgatos-Garcia, S., Touriki, G., Dragosloveanu, C. D. M., Căruntu, A., Săvulescu-Fiedler, I., Dragosloveanu, Ş., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030204 · Cited by 21
Tetenta, S., & Metersky, M. L. (2010) · Respirology · doi:10.1111/j.1440-1843.2010.01855.x · Cited by 17
Chung, D. R., Lee, C., Kang, Y. R., Baek, J. Y., Ys, K., Ha, Y. E., Kang, C., Peck, K. R., Lee, N. Y., & Song, J. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.03.009 · Cited by 17
Heterogeneous vancomycin-intermediate among methicillin resistant Staphylococcus aureus
Chaudhari, C., Tandel, K., Grover, N., Sen, S., Bhatt, P., Sahni, A. K., & Praharaj, A. K. (2014) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2014.03.008 · Cited by 17
Peppard, W., Juul, J. J., Mullins, C., & Huang, A. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s71855 · Cited by 17
Miller, S. A., Karichu, J. K., Kohner, P. C., Cole, N. C., Hindler, J. A., Patel, R., Richter, S. S., & Humphries, R. M. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02211-16 · Cited by 17
Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline
Turner, R. B., Wilson, D. E., Saedi-Kwon, H., Chang, E., Won, R., Chan, D., & Schwartz, J. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx452 · Cited by 17
Doddangoudar, V. C., Boost, M. V., Tsang, D. N. C., & O'Donoghue, M. M. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03463.x · Cited by 17
Parer, S., Lotthé, A., Chardon, P., Poncet, R., Jean‐Pierre, H., & Jumas‐Bilak, E. (2012) · Infection Control and Hospital Epidemiology · doi:10.1086/663703 · Cited by 17
Doddangoudar, V. C., O'Donoghue, M. M., Chong, E. Y. C., Tsang, D. N. C., & Boost, M. V. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks171 · Cited by 17
Zendejas-Manzo, G. S., Avalos-Flores, H., & Padilla, M. Y. S. (2014) · Dialnet (Universidad de la Rioja) · doi:10.32776/revbiomed.v25i3.42 · Cited by 17
Kalali, Y., Haghighat, S., & Mahdavi, M. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.11.010 · Cited by 17
Foster, T. J., & Geoghegan, J. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00026-5 · Cited by 18
Host-Targeted Therapeutics against Multidrug Resistant Intracellular Staphylococcus aureus
Bravo-Santano, N., Behrends, V., & Letek, M. (2019) · Antibiotics · doi:10.3390/antibiotics8040241 · Cited by 16
Molecular Mechanisms of Antimicrobial Resistance in Staphylococcus aureus Biofilms
SILVA, V. Y. N. E. D., Capelo, J. L., Igrejas, G., & Poeta, P. A. C. Q. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-84126-3_12 · Cited by 16
Millette, G., Séguin, D. L., Isabelle, C., Chamberland, S., Lucier, J., Rodrigue, S., Cantin, A. M., & Malouin, F. (2023) · Antibiotics · doi:10.3390/antibiotics12061069 · Cited by 17
Structure–activity relationship study of novel iminothiadiazolo-pyrimidinone antimicrobial agents
Paudel, A., Kaneko, K., Watanabe, A., Matsunaga, S., Kanai, M., Hamamoto, H., & Sekimizu, K. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.69 · Cited by 16
Bhandari, V., Chakraborty, S., Brahma, U., & Sharma, P. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00365 · Cited by 16
Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America
Castro, B. E., Berrío-Pérez, M., Vargas, M. L., Carvajal, L. P., Millán, L. V., Ríos, R., Hernandez, A. K., Rincón, S., Cubides, P., Forero, E., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa221 · Cited by 17
De Novo Resistance to Arg 10 -Teixobactin Occurs Slowly and Is Costly
Lloyd, D. G., Schofield, B. J., Goddard, M. R., & Taylor, E. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01152-20 · Cited by 16
Rani, N. N. I. M., Hussein, Z. M., Mustapa, F., Azhari, H., Sekar, M., Chen, X. Y., & Amin, M. C. I. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.04.021 · Cited by 17
Guo, Y., Wang, B., Rao, L., Wang, X., Zhao, H., Li, M., & Yu, F. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s336200 · Cited by 16
In vitro vancomycin susceptibility amongst methicillin resistant Staphylococcus aureus
Chaudhari, C., Tandel, K., Grover, N., Bhatt, P., Sahni, A. K., Sen, S., & Prahraj, A. (2014) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2013.11.008 · Cited by 16
Tevell, S., Claesson, C., Hellmark, B., Söderquist, B., & Nilsdotter‐Augustinsson, Å. (2013) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2025-3 · Cited by 16
Othman, H. B., Halim, R. M. A., Gomaa, F. A. M., & Amer, M. Z. (2018) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.009 · Cited by 16
[Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].
Rincón, S., Panesso, D., Díaz, L., Carvajal, L. P., Reyes, J., Munita, J. M., & Arias, C. A. (2014) · PubMed · doi:10.1590/s0120-41572014000500022 · Cited by 16
Emergence and Spread of Antimicrobial-Resistant Pathogens in an Era of Globalization
Senok, A. C., Botta, G. A., & Soge, O. O. (2012) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2012/286703 · Cited by 16
Multari, R. A., Cremers, D. A., Bostian, M. L., Dupre, J. M., & Gustafson, J. E. (2013) · Journal of Pathogens · doi:10.1155/2013/898106 · Cited by 17
Koh, Y. R., Kim, N., Chang, C. L., & Yi, J. (2016) · Annals of Laboratory Medicine · doi:10.3343/alm.2016.36.3.235 · Cited by 15
VanA-Type MRSA (VRSA) Emerged in Surface Waters
İçgen, B. (2016) · Bulletin of Environmental Contamination and Toxicology · doi:10.1007/s00128-016-1827-2 · Cited by 15
Goddard, T. N., Patel, J. R., Park, H. B., & Crawford, J. M. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00213 · Cited by 15
Gowrisankar, Y. V., Mudhu, S. M., Pasupuleti, S. K., Suthi, S., Chaudhury, A., & Sarma, P. V. G. K. (2020) · Canadian Journal of Microbiology · doi:10.1139/cjm-2020-0434 · Cited by 15
Ghasemian, A., Peerayeh, S. N., Bakhshi, B., & Mirzaee, M. (2015) · Archives of Pediatric Infectious Diseases · doi:10.5812/pedinfect.20703v2 · Cited by 15
Studies on the Mechanism of Telavancin Decreased Susceptibility in a Laboratory-Derived Mutant
Song, Y., Lunde, C. S., Benton, B. M., & Wilkinson, B. J. (2013) · Microbial Drug Resistance · doi:10.1089/mdr.2012.0195 · Cited by 15
Vaudaux, P. E., Ferry, T., Uçkay, İ., François, P., Schrenzel, J., Harbarth, S., & Renzoni, A. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1705-8 · Cited by 15
Tenover, F. C. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.005 · Cited by 15
Use of Daptomycin to Manage Severe MRSA Infections in Humans
Fiore, M., Alfieri, A., Fiore, D., Iuliano, P., Spatola, F. G., Limone, A., Pezone, I., & Leone, S. (2025) · Antibiotics · doi:10.3390/antibiotics14060617 · Cited by 16
Burgin, D. J., Liu, R., Hsieh, R. C., Heinzinger, L. R., & Otto, M. J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2040015 · Cited by 14
Alfadil, A., Alzahrani, A. M., Abdullah, H., Alsamhan, H., Abujamel, T. S., Ahmed, H., & Jiman-Fatani, A. A. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s401371 · Cited by 14
Laliwala, A., Gupta, R., Svechkarev, D. A., Bayles, K. W., Sadykov, M. R., & Mohs, A. M. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.111395 · Cited by 14
Chen, F.-J., Lauderdale, T.-L. Y., Wang, L.-S., & Huang, I. (2013) · Genome Announcements · doi:10.1128/genomea.01011-13 · Cited by 14
Kwong, J. C., Chua, K., & Charles, P. G. P. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0254-8 · Cited by 13
Takata, T., Miyazaki, M., Futo, M., Hara, S., Shiotsuka, S., Kamimura, H., Yoshimura, H., Matsunaga, A., Nishida, T., Ishikura, H., et al. (2012) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2012.723221 · Cited by 14
Sancak, B., Yağcı, S., Mirza, H. C., & Hasçelik, G. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt247 · Cited by 14
Khatib, R., RIEDERER, K. M., Sharma, M., Shemes, S. P., Iyer, S. P., & Szpunar, S. M. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.01620-15 · Cited by 14
Gregorio, S. D., Fernández, S., Perazzi, B. E., Bello, N., Famiglietti, A. M. R., & Mollerach, M. E. (2016) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2016.05.001 · Cited by 14
Substrate Inhibition of VanA by d -Alanine Reduces Vancomycin Resistance in a VanX-Dependent Manner
van der Aart, L. T., Lemmens, N., van Wamel, W. J. B., & van Wezel, G. P. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00276-16 · Cited by 14
Su, M., Davis, M. H., Peterson, J., Solís‐Lemus, C., Satola, S. W., & Read, T. D. (2021) · PeerJ · doi:10.7717/peerj.11764 · Cited by 14
Eckmann, C., & Tulkens, P. M. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab351 · Cited by 15
Mechanisms of Resistance to Antibacterial Agents
Patel, J. B., & Richter, S. S. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch69 · Cited by 16
Permeability of Bacteria to Antibacterial Agents
Nichols, W. W. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1400-1_26 · Cited by 14
Totally-drug-resistant tuberculosis: hype versus hope
Maeurer, M. J., Schito, M. L., & Zumla, A. I. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70020-7 · Cited by 14
Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia
Espedido, B. A., Jensen, S. O., & van Hal, S. J. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku455 · Cited by 14
Souli, M., Karaiskos, I., Galani, L., Maraki, S., Perivolioti, E., Argyrοpoulou, A., Charissiadou, A., Zachariadou, L., Tsiplakou, S., Papaioannou, V., et al. (2015) · Scandinavian Journal of Infectious Diseases · doi:10.3109/23744235.2015.1110858 · Cited by 14
Population Genomics of Reduced Vancomycin Susceptibility in Staphylococcus aureus
Rishishwar, L., Kraft, C. S., & Jordan, I. K. (2016) · mSphere · doi:10.1128/msphere.00094-16 · Cited by 14
Mechanisms and Detection of Antimicrobial Resistance
Alby, K., & Miller, M. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00290-5 · Cited by 14
Hos, N. J., Jazmati, N., Stefanik, D., Hellmich, M., AlSael, H., Kern, W. V., Rieg, S., Wisplinghoff, H., Seifert, H., & Kaasch, A. J. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.12.007 · Cited by 14
Metadata
- Authors
- Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L.
- Affiliations
- The University of Melbourne (AU)
- Monash University (AU)
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2010-01
- Volume
- 23
- Issue
- 1
- Pages
- 99-139
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- PMC
- PMC2806658
- OpenAlex
- W2126915534
- Cited by
- 962
- References
- 406
- Citations by year
- 2026: 42 · 2025: 41 · 2024: 48 · 2023: 58 · 2022: 45 · 2021: 52 · 2020: 49 · 2019: 60 · 2018: 54 · 2017: 51 · 2016: 63 · 2015: 83 · 2014: 69 · 2013: 88 · 2012: 72
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Microbiology Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin-intermediate Staphylococcus aureus, heterogeneous vancomycin-intermediate Staphylococcus aureus, reduced vancomycin susceptibility, glycopeptide resistance, cell wall thickening, agr gene, vancomycin susceptibility testing, treatment failure, host-pathogen interaction
- MeSH terms
- Anti-Bacterial Agents, Humans, Microbial Sensitivity Tests, Staphylococcal Infections, Staphylococcus aureus, Vancomycin, Treatment Outcome, Vancomycin Resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
